These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22203473)

  • 1. Mutational activation of FGFR3: no involvement in the development of renal cell carcinoma.
    Stoehr CG; Stoehr R; Hartmann A; Hofstaedter F; Junker K; Blaszyk H; Wieland WF; Otto W; Denzinger S; Walter B
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):359-61. PubMed ID: 22203473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR3 mutation in thanatophoric dysplasia type 1 with bilateral cystic renal dysplasia: coincidence or a new association?
    Prontera P; Sensi A; Pilu G; Baldi M; Baffico M; Bonasoni R; Calzolari E
    Genet Couns; 2006; 17(4):407-12. PubMed ID: 17375526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
    Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
    Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia.
    Guo C; Degnin CR; Laederich MB; Lunstrum GP; Holden P; Bihlmaier J; Krakow D; Cho YJ; Horton WA
    Cell Signal; 2008 Aug; 20(8):1471-7. PubMed ID: 18485666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.
    Jin M; Yu Y; Qi H; Xie Y; Su N; Wang X; Tan Q; Luo F; Zhu Y; Wang Q; Du X; Xian CJ; Liu P; Huang H; Shen Y; Deng CX; Chen D; Chen L
    Hum Mol Genet; 2012 Dec; 21(26):5443-55. PubMed ID: 23014564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced binding of FGF1 to mutant fibroblast growth factor receptor 3.
    Khnykin D; Olsnes S
    Growth Factors; 2006 Jun; 24(2):111-9. PubMed ID: 16801131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR3 gene mutations in Chinese cases of thanatophoric dysplasia type 1.
    Yang Y; Li DZ
    Fetal Diagn Ther; 2009; 26(2):90-2. PubMed ID: 19752524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix.
    Wu R; Connolly D; Ngelangel C; Bosch FX; Muñoz N; Cho KR
    Oncogene; 2000 Nov; 19(48):5543-6. PubMed ID: 11114733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.
    Knowles MA
    World J Urol; 2007 Dec; 25(6):581-93. PubMed ID: 17912529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.
    Kimura T; Suzuki H; Ohashi T; Asano K; Kiyota H; Eto Y
    Cancer; 2001 Nov; 92(10):2555-61. PubMed ID: 11745189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines.
    Tomlinson DC; L'Hôte CG; Kennedy W; Pitt E; Knowles MA
    Cancer Res; 2005 Nov; 65(22):10441-9. PubMed ID: 16288035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thanatophoric dysplasia caused by double missense FGFR3 mutations.
    Pannier S; Martinovic J; Heuertz S; Delezoide AL; Munnich A; Schibler L; Serre V; Legeai-Mallet L
    Am J Med Genet A; 2009 Jun; 149A(6):1296-301. PubMed ID: 19449430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.
    Webster MK; D'Avis PY; Robertson SC; Donoghue DJ
    Mol Cell Biol; 1996 Aug; 16(8):4081-7. PubMed ID: 8754806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
    Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
    Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
    Ota S; Zhou ZQ; Romero MP; Yang G; Hurlin PJ
    Hum Mol Genet; 2016 Oct; 25(19):4227-4243. PubMed ID: 27506979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel insertion mutation in FGFR3 that causes thanatophoric dysplasia type 1.
    Lindy AS; Basehore MJ; Munisha M; Williams AL; Friez MJ; Writzl K; Willems P; Dougan ST
    Am J Med Genet A; 2016 Jun; 170(6):1573-9. PubMed ID: 27028100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
    Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
    Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II.
    Shung CY; Ota S; Zhou ZQ; Keene DR; Hurlin PJ
    Hum Mol Genet; 2012 Nov; 21(21):4628-44. PubMed ID: 22843502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid detection of common mutations of the FGFR3 gene causing thanatophoric dysplasia type I: two case reports.
    Yang Y; Liu YN; Li DZ
    Fetal Pediatr Pathol; 2012 Jun; 31(3):128-33. PubMed ID: 22414243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.